

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO.   | FILING DATE    | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |
|---|----------------|----------------------|-------------------------|------------------|
| 09/623,140  | 08/28/2000     | Masaaki Nakamura     | Q 59949                 | 9670             |
| 7:  | 590 12/11/2002 |                      |                         |                  |
| Sughrue Mion Zinn Macpeak & Seas<br>2100 Pennsylvania Avenue N W<br>Washington, DC 20037-3202 |                |                      | EXAMINER                |                  |
|   |                |                      | CAIN, EDWARD J          |                  |
|   |                |                      | ART UNIT                | PAPER NUMBER     |
|   |                |                      | 1714                    | 12               |
|   |                |                      | DATE MAILED: 12/11/2002 |                  |

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER FILING DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO.

EXAMINER

ART UNIT

DATE MAILED:

PAPER NUMBER

Below is a communication from the *EXAMINER* in charge of this application COMMISSIONER OF PATENTS AND TRADEMARKS

ADVISORY ACTION THE REPLY FILED FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. The REPLY FILED FALLS TO PLACE THIS AFFLICATION IN CONDITION FOR ALLEANANCE.

Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. PERIOD FOR REPLY [check only a) or b)] The period for reply expires 4 months from the mailing date of the final rejection. b) In view of the early submission of the proposed reply (within two months as set forth in MPEP § 707.07(f)), the period for reply expires on the mailing date of this Advisory Action, OR continues to run from the mailing date of the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any med patent term adjustment. See 37 CFR 1.704(b). . Appellant's Brief must be filed within the period set forth in 1. A Notice of Appeal was filed on \_ 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. The proposed amendment(s) will be entered upon the timely submission of a Notice of Appeal and Appeal Brief with requisite fees. 3. The proposed amendment(s) will not be entered because: (a) \( \square\) they raise new issues that would require further consideration and/or search. (see NOTE below); (b) they raise the issue of new matter. (see NOTE below); (c) \( \subseteq \) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) they present additional claims without canceling a corresponding number of finally rejected claims. NOTE: 4. Applicant's reply has overcome the following rejection(s): would be allowable if submitted in a 5. Newly proposed or amended claim(s)\_ separate, timely filed amendment canceling the non-allowable claim(s). 6. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: \_ 7. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection. 8. For purposes of Appeal, the status of the claim(s) is as follows (see attached written explanation, if any): Claim(s) allowed: \_ Claim(s) objected to: \_ Claim(s) rejected: \_\_\_ 0 Claim(s) withdrawn from consideration: \_\_\_\_ 9. The proposed drawing correction filed on \_\_\_\_\_ \_ a) ☐ has b) ☐ has not been approved by the Examiner.

10. Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_.

EDWARD J. CAIN PRIMARY EXAMINER GROUP 1500

11. 12 Other: Sce attachment

Application/Control Number: 09/623,140

Art Unit:

## **Attachment to Advisory**

Applicants recitation of self-crosslinkable polymer A is not seen as distinguishing over the polymers of the prior art of record. Neither Applicants claims nor specification provides clear guidance as to what Applicants consider a self-crosslinkable polymer to encompass. It cannot be ascertained which functional groups are included or excluded.

1. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *Edward Cain* whose telephone number is (703) 308-0042.

**Edward Cain** 

December 9, 2002

EDWARD J. CAIN PRIMARY EXAMINER GROUP 1500